1Carbon C. Comparison of side effects of Levofloxacin versus other fluoroquinolones[J ]. Chemotherapy, 2001,47, (suppl3):9.
2Ball P. Safety of the new fluoroquinolones compared with Ciprofloxacin[J]. Chemotherapy, 2002,48, (suppl 1 ) : 8.
3Sahlmann R. Clinical toxicological aspects of fluoroquinolones[J]. Toxicology Letters, 2002,127:269.
4Labro M T, Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno- fairy Tales"? [J]. Clin Microbiol Rev, 2000, 13(4)-615.
5Kang JS, Wang L, Chen XL, et al. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K^+ channel HERG EJ]. Mol Pharmaco1,2001,59(1):122.
6Ball P. Quinolone - induced QT interval prolongation: a not-so- unexpected class effect[J ]. J Antirnicrob Chemother,2002,45 : 557.
7Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones[J ]. J Antimicrob Chemother , 2002,49: 593.
8Anderson M, Mazur E, Yang A, et al. Comparison of K^+ current antagonistic properties and proarrythrnic consequences of gatifloxacin, grepafloxacin and sparfloxacin.[C] madrid, Abstract In Program and Abstracts of the Third European Congress of Chemotherapy, 2000. M161.
9Stahlmann R, Zippel U, Forster C, et al. Chondrotoxicity and toxicokinetics of sparfloxacin in juvenile rats [J]. Antimicrob Agents Chemother , 1998,42:1470.
10Stahlmann R, Forster C, Shakibaei M, et al. Magnesium deftciency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy[J]. Antimicrob Agents Chemother , 1995,39:2013.
